Promis Neurosciences (NASDAQ:PMN) Upgraded by Zacks Research to “Hold” Rating

Promis Neurosciences (NASDAQ:PMN) was upgraded by research analysts at Zacks Research to a “hold” rating in a research note issued on Tuesday,Zacks.com reports.

Other equities analysts have also recently issued research reports about the company. Wall Street Zen raised Promis Neurosciences from a “strong sell” rating to a “sell” rating in a report on Sunday, May 31st. Brookline Capital Markets raised Promis Neurosciences to a “strong-buy” rating in a report on Wednesday, May 20th. Finally, HC Wainwright reaffirmed a “buy” rating and issued a $18.00 target price on shares of Promis Neurosciences in a report on Monday. One equities research analyst has rated the stock with a Strong Buy rating, two have given a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $26.50.

Promis Neurosciences Stock Performance

NASDAQ:PMN opened at $10.20 on Tuesday. The stock has a fifty day moving average price of $10.97 and a 200-day moving average price of $12.04. The company has a market cap of $91.49 million, a price-to-earnings ratio of -0.70 and a beta of -0.19. Promis Neurosciences has a fifty-two week low of $6.27 and a fifty-two week high of $39.75.

Promis Neurosciences (NASDAQ:PMN) last released its earnings results on Tuesday, May 12th. The company reported ($1.26) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.06) by ($0.20). Research analysts predict that Promis Neurosciences will post -4.57 EPS for the current fiscal year.

Insider Transactions at Promis Neurosciences

In related news, Director Patrick D. Kirwin purchased 4,000 shares of Promis Neurosciences stock in a transaction on Wednesday, April 22nd. The shares were purchased at an average price of $11.33 per share, for a total transaction of $45,320.00. Following the transaction, the director owned 4,653 shares of the company’s stock, valued at approximately $52,718.49. This represents a 612.56% increase in their position. The purchase was disclosed in a legal filing with the SEC, which is available at this hyperlink. 1.50% of the stock is currently owned by insiders.

Institutional Investors Weigh In On Promis Neurosciences

A number of institutional investors have recently made changes to their positions in the stock. Seven Fleet Capital Management LP bought a new stake in shares of Promis Neurosciences in the 1st quarter valued at about $135,000. Janus Henderson Group PLC bought a new stake in shares of Promis Neurosciences in the 1st quarter valued at about $16,418,000. Ally Bridge Group NY LLC grew its position in shares of Promis Neurosciences by 66.1% in the 1st quarter. Ally Bridge Group NY LLC now owns 414,219 shares of the company’s stock valued at $5,261,000 after buying an additional 164,880 shares during the last quarter. Yu Fan bought a new stake in shares of Promis Neurosciences in the 1st quarter valued at about $4,188,000. Finally, ADAR1 Capital Management LLC bought a new stake in shares of Promis Neurosciences in the 1st quarter valued at about $1,211,000. Institutional investors own 50.13% of the company’s stock.

More Promis Neurosciences News

Here are the key news stories impacting Promis Neurosciences this week:

• Positive Sentiment: HC Wainwright maintained a Buy rating on Promis Neurosciences and kept an $18 price target, signaling continued analyst optimism about the stock’s upside.
• Positive Sentiment: HC Wainwright raised its FY2026 EPS estimate to ($4.57) from ($4.95), indicating a somewhat improved earnings outlook for Promis Neurosciences.
• Positive Sentiment: The firm also lifted its Q2 2026 EPS estimate to ($1.01) from ($1.54), another relatively better forecast for near-term performance.
• Neutral Sentiment: HC Wainwright issued updated EPS estimates for several future quarters, but these remained losses through FY2027, so the revisions were mixed overall and did not change the broader unprofitable profile of the company.
• Negative Sentiment: Some quarterly estimates were lowered or remain deeply negative, including Q4 2026 at ($1.20), which suggests Promis Neurosciences is still expected to burn cash and post losses for the foreseeable future.

Promis Neurosciences Company Profile

Promis Neurosciences, Inc is a clinical‐stage biopharmaceutical company focused on the discovery and development of novel therapeutics for central nervous system disorders. The company’s research programs target cognitive impairment and other neurological symptoms associated with diseases such as Alzheimer’s disease and multiple sclerosis.

Leveraging a proprietary small‐molecule discovery platform, Promis Neurosciences advances both preclinical and early clinical candidates designed to modulate neural pathways involved in memory, learning and neuroinflammation.